GTPBP1 and COVID-19: Weakly positive anti-cardiolipin and anti-B2-GP1 IgM (no IgG) were also described in 2 of 24 (8.3%) of patients in a cohort of COVID-19 patients in Madrid with confirmed VTE (45).